A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2023-07-14
AEs
3
Serious
1
Dropout signal
–
Adverse events
severe
serious
assessed
Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-12-16 (study day 150); relationship: N; serious criteria: hospitalization
moderate
assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-05-22 (study day 308); relationship: not assessed
mild
assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-09-02 (study day 411); relationship: Y
Data queries
No data queries.